Ajit Mishra, vice president, Research, Religare Broking, answers your queries
Costlier oil due to rising conflict in Iraq threatens to hurt the India economy that is already battling price rise and slowing growth.
The S&P BSE Sensex dropped 207 points to end at 25,230.
Drugs under exemption make up roughly 95 per cent of the antiretrovirals used by India's AIDS patients
The B-school also witnessed new roles in the domain.
S&P BSE Midcap and the S&P BSE Smallcap indices gained 2% and 1.6% respectively
'The majority of the spread is by people coughing, or sneezing or talking loudly, in a very short distance, two metres from one another, and a mask will prevent that sort of transmission.'
Even as the Supreme Court had recently dismissed the industry's plea against prices fixed by the regulator and its timely implementation, the National Pharmaceutical Pricing Authority has asked companies to pay the overcharged dues with 15 per cent interest.
Ajit Mishra, Vice President, Research, Religare Broking, answers readers' stock market queries. Ajit will offer his unbiased views on a weekly basis
Low growth visibility and trouble with regulators have resulted in lack of interest from investors
India serves as the company's R&D hub as it morphs into a health tech major.
A recent report has suggested that future patent expires in the cardiac and anti-diabetes space would form a good opportunity for smaller firms, given their franchise in these segments.
.jpg)
The move is expected to delay the introduction of low-priced medicines in the market.
Total exit value breached the $10 billion mark for the first time to touch $10.3 billion this calendar, from $9.4 billion in 2015
FMCG, durables, pharma firms say they remain unclear about transition gains and losses
Dilip Shanghvi has never tried to be everything to everybody.
The sentiment-driven rally also got support from stock specific earning results and Finance Minister Arun Jaitley's statement that the Centre will step up reforms to attract more investment and fill up infrastructure deficit.
Hero MotoCorp's promoter Pawan Munjal emerged as the highest paid director.
Of the 30-share Sensex, 13 ended higher, while 17 led by Power Grid, Tata Steel, Bajaj Auto, Hero MotoCorp, NTPC, Tata Motors, Dr Reddy's, M&M, GAIL, Infosys and L&T finished lower, fell by up to 2.40 per cent
Benchmark indices plunge 4.7% in the first full week of 2016.
An innovator creates intellectual property for a need no one knows exists, says Chandru Chawla.
'The majority of transmission will be via people who are within two metres of one another.' 'The closer you are, the more likely that you'll be infected.'
Analysts say those taking exposure through stocks could look at firms focused on domestic business
Ajit Mishra, vice president, Research, Religare Broking, answers your queries:
The 50-share NSE Nifty was trading lower by 24 points.
.jpg)
The debt-equity ratio was as high as 1.4 times the net worth as certificates of deposit and inter-corporate deposits gained popularity.
'Pay-for-delay' settlements between drug patent-holders and generics manufacturers to delay the launch of cheaper generic medicine are increasingly being scrutinised by antitrust regulators
The BSE Midcap and Smallcap indices underperformed the largecaps and ended over 1% lower.
While the government's demonetisation move is aimed at curbing under-invoicing, the worry was that retailers would de-stock in the short term, impacting sales.
Dilip Shanghvi founded Sun Pharma in 1983.
Earning woes drag markets lower; TCS, HUL lead fall.
Better-than-expected financial results in Q3 due to higher revenue growth and margins in key markets fuel the rally
The BSE benchmark index is yet to give any indication on the monthly Fibonacci charts.
The Delhi High Court on Friday stayed the ban on some fixed dose combination (FDC) drugs of Glaxo SmithKline, Wockhardt and Laboratories Griffon but said action against their sale could be taken in the absence of valid sale and marketing licence.
Asian markets were trading mixed with the Nikkei gaining after the US dollar strengthened against the yen.
The recovery was led by pharma majors led by Dr Reddy's Labs.
Indian loses chance to be research hub as domestic drug companies move R&D overseas.
Ajit Mishra, Vice President, Research, Religare Broking, answers readers' queries on stocks they own or want to buy.
The former McKinsey India head is presently on board of many big Indian conglomerates.
Geopolitical concerns, earnings sees investors rush to safe haven plays post the Union Budget presentation in July.
